Welcome to LookChem.com Sign In|Join Free
  • or
5-(tert-butoxycarbonylamino)-2-(butyryloxy)benzoic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1351504-01-2

Post Buying Request

1351504-01-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1351504-01-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1351504-01-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,1,5,0 and 4 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1351504-01:
(9*1)+(8*3)+(7*5)+(6*1)+(5*5)+(4*0)+(3*4)+(2*0)+(1*1)=112
112 % 10 = 2
So 1351504-01-2 is a valid CAS Registry Number.

1351504-01-2Relevant academic research and scientific papers

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS

-

, (2019/12/28)

Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated hydroxybenzoic acids), active agent combinations (e.g., with a second agent that is a fatty acid) and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

-

, (2019/12/28)

Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME

-

, (2019/01/06)

Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.

NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES

-

, (2013/04/10)

The present invention refers to the compounds corresponding to the following general formula (I): wherein: R═C4-C8 alkanoyl; andX═NH—R1 where R1═H, or an amine protecting group;and/or the pharmaceutically accept

NOVEL DERIVATIVES OF MESALAZINE, PROCESS OF THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES

-

Page/Page column 10-11, (2011/12/14)

The present invention refers to the compounds corresponding to the following general formula (I): (I) wherein: R = C4-C8 alkanoyl; and X = NH-R1 where R1 = H, or an amine protecting group; and/or the pharmaceuti

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1351504-01-2